货号 | AF6214-SP |
别名 | KIAA1032Munc13-1protein unc-13 homolog A; Munc13-1; unc-13 homolog A (C. elegans) | 全称 | UNC-13 homolog A |
反应种属 | Human/Mouse |
应用 | Western Blot(2 µg/mL) |
目标/特异性 | Detects human and mouse UNC13A in Western blots. |
使用方法 | Western Blot: 2 µg/mL |
来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 23025 (Human); 382018 (Mouse); 64829 (Rat) |
纯化方式 | Antigen Affinity-purified |
免疫原 | E. coli-derived recombinant human UNC13A Asp1525-Gly1698 Accession # Q9UPW8 |
生物活性 | Human, Mouse |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
背景 | UNC13A (UNCoordinated 13A; also Munc13-1) is a 190‑210 kDa member of the UNC-13 family, C2 domain protein superfamily of molecules. It is expressed at synaptic junctions, particularly those involved in GABA, acetylcholine and glutamine transmission, and appears to be necessary for neurotransmitter release. In the presynaptic region, UNC13A likely interacts with syntaxin 1, converting it from a closed to an open configuration, thus allowing for SNARE complex formation. Human UNC13A is 1703 amino acids (aa) in length. It contains one C2 domain that mediates dimerization (aa 1‑79), a coiled‑coil region (aa 320‑357), one DAG Zn‑finger region (aa 553‑603), a second C2 domain (aa 663‑769), two MHD domains (aa 1093‑1512) and a third C2 domain (aa 1532‑1637). Western blots of mouse UNC13A show 105 kDa and 70 kDa forms. Over aa 1525‑1698, human UNC13A shares 98% aa identity with mouse UNC13A. |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Detection of Human and Mouse UNC13A by Western Blot. Western blot shows lysates of human brain (hippocampus) tissue and mouse brain tissue. PVDF Membrane was probed with 2 µg/mL of Sheep Anti-Human/Mouse UNC13A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6214) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for UNC13A at approximately 190-210 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 2. |